Amifampridine
- Generic Name
- Amifampridine
- Brand Names
- Firdapse, Ruzurgi, Firdapse (previously Zenas), Amifampridine SERB
- Drug Type
- Small Molecule
- Chemical Formula
- C5H7N3
- CAS Number
- 54-96-6
- Unique Ingredient Identifier
- RU4S6E2G0J
- Background
Amifampridine, or 3,4-diaminopyridine (3,4-DAP), is a quaternary ammonium compound that blocks presynaptic potassium channels, and subsequently prolongs the action potential and increases presynaptic calcium concentrations . It was first discovered in Scotland in the 1970s and its clinical effectiveness for neuromuscular disorders, including Lambert–Eaton my...
- Indication
用于治疗6岁及以上的成人和儿童患者的一种罕见病自身免疫疾病兰伯特-伊顿（Lambert Eaton）肌无力综合征（LEMS）。LEMS最常见的表现是肌无力，容易疲劳，可导致行走及爬楼梯困难。
- Associated Conditions
- Lambert Eaton Myasthenic Syndrome (LEMS)
- Associated Therapies
- -
Effect of Amifampridine on Neuromuscular Transmission in Patients Treated With OnabotulinumtoxinA
- First Posted Date
- 2023-03-15
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Wake Forest University Health Sciences
- Target Recruit Count
- 20
- Registration Number
- NCT05769478
- Locations
- 🇺🇸
Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States
Firdapse for Post-BOTOX Vocal Weakness
- First Posted Date
- 2021-11-17
- Last Posted Date
- 2023-05-26
- Lead Sponsor
- Augusta University
- Target Recruit Count
- 10
- Registration Number
- NCT05123053
- Locations
- 🇺🇸
Augusta University, Augusta, Georgia, United States
Treatment Use of 3,4 Diaminopyridine in Congenital Myasthenia
- Conditions
- First Posted Date
- 2017-02-23
- Last Posted Date
- 2023-06-02
- Lead Sponsor
- Ricardo Maselli
- Registration Number
- NCT03062631
- Locations
- 🇺🇸
University of California, Davis Medical Center, Sacramento, California, United States
3,4-Diaminopyridine for Lambert-Eaton Myasthenic Syndrome (LEMS) and Congenital Myasthenia (CM)
- First Posted Date
- 2013-12-17
- Last Posted Date
- 2019-12-11
- Lead Sponsor
- Oregon Health and Science University
- Registration Number
- NCT02012933
- Locations
- 🇺🇸
Oregon Health & Science University, Portland, Oregon, United States
Treatment Use of 3,4-Diaminopyridine
- Conditions
- First Posted Date
- 2013-01-10
- Last Posted Date
- 2024-01-05
- Lead Sponsor
- Vern C. Juel, M.D.
- Registration Number
- NCT01765140
- Locations
- 🇺🇸
Duke University Hospital, Durham, North Carolina, United States
Pilot Study on the Usefulness of 3,4-diaminopyridine in the Treatment of Botulism
- Conditions
- First Posted Date
- 2011-09-27
- Last Posted Date
- 2016-04-28
- Lead Sponsor
- Centre Hospitalier Universitaire, Amiens
- Target Recruit Count
- 3
- Registration Number
- NCT01441557
- Locations
- 🇫🇷
CHU, Amiens, France
Treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) With 3, 4 DAP
- Conditions
- First Posted Date
- 2011-06-22
- Last Posted Date
- 2013-07-18
- Lead Sponsor
- Louis H. Weimer, MD
- Registration Number
- NCT01378546
- Locations
- 🇺🇸
Columbia University Medical Center, New York, New York, United States
Treatment of Lambert-Eaton Syndrome With 3,4 Diaminopyridine
- Conditions
- First Posted Date
- 2009-10-14
- Last Posted Date
- 2019-07-09
- Lead Sponsor
- David Lacomis, MD
- Registration Number
- NCT00994916
3,4-Diaminopyridine Use in Lambert-Eaton Myasthenic Syndrome(LEMS) and Congenital Myasthenic Syndromes (CMS)
- First Posted Date
- 2009-04-01
- Last Posted Date
- 2022-04-11
- Lead Sponsor
- Lahey Clinic
- Registration Number
- NCT00872950
- Locations
- 🇺🇸
Lahey Hospital & Medical Center, Burlington, Massachusetts, United States
Fatigue in Multiple Sclerosis: Evaluated With 3 MRI and Transcranial Magnetic Stimulation
- Conditions
- Interventions
- First Posted Date
- 2006-06-21
- Last Posted Date
- 2007-12-17
- Lead Sponsor
- University of Aarhus
- Target Recruit Count
- 120
- Registration Number
- NCT00342381
- Locations
- 🇩🇰
Aarhus University Hospital, Department of Neurology, Aarhus, Denmark
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.